Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cindy H Chau

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Pharmacotherapy|July 10, 2020
COVID-19 Clinical Diagnostics and Testing TechnologyCindy H Chau, Jonathan D Strope, William D Figg
Seminars in Oncology|July 15, 2020
Are sex discordant outcomes in COVID-19 related to sex hormones?Jonathan D Strope, Cindy H Chau, William D Figg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Validation of analytic methods for biomarkers used in drug developmentCindy H Chau, Olivier Rixe, Howard McLeod, et al.
Cancer Biology & Therapy|February 7, 2022
Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activomeKristi Y Lee, Cindy H Chau, Douglas K Price, et al.
American Journal of Clinical and Experimental Urology|September 2, 2022
PARP inhibitors on the move in prostate cancer: spotlight on Niraparib & update on PARP inhibitor combination trialsErica L Beatson, Cindy H Chau, Douglas K Price, et al.
Nature Clinical Practice. Urology|February 14, 2006
Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancerArun S Singh, Cindy H Chau, Douglas K Price, et al.
Journal of Clinical Pharmacology|May 21, 2016
Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer TreatmentKeith T Schmidt, Cindy H Chau, Douglas K Price, et al.
American Journal of Clinical and Experimental Urology|June 3, 2021
Diversity on demand: multi-ancestry meta-analysis improves genetic risk prediction in prostate cancerAndres F Leon, Cindy H Chau, Douglas K Price, et al.
American Journal of Clinical and Experimental Urology|September 15, 2020
BETting on next-generation bromodomain inhibitorsMatthew K Collins, Cindy H Chau, Douglas K Price, et al.
Cancers|May 5, 2021
Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease ManagementDavid K Doan, Keith T Schmidt, Cindy H Chau, et al.
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Pharmacotherapy|July 10, 2020
COVID-19 Clinical Diagnostics and Testing TechnologyCindy H Chau, Jonathan D Strope, William D Figg
Seminars in Oncology|July 15, 2020
Are sex discordant outcomes in COVID-19 related to sex hormones?Jonathan D Strope, Cindy H Chau, William D Figg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Validation of analytic methods for biomarkers used in drug developmentCindy H Chau, Olivier Rixe, Howard McLeod, et al.
Cancer Biology & Therapy|February 7, 2022
Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activomeKristi Y Lee, Cindy H Chau, Douglas K Price, et al.
American Journal of Clinical and Experimental Urology|September 2, 2022
PARP inhibitors on the move in prostate cancer: spotlight on Niraparib & update on PARP inhibitor combination trialsErica L Beatson, Cindy H Chau, Douglas K Price, et al.
Nature Clinical Practice. Urology|February 14, 2006
Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancerArun S Singh, Cindy H Chau, Douglas K Price, et al.
Journal of Clinical Pharmacology|May 21, 2016
Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer TreatmentKeith T Schmidt, Cindy H Chau, Douglas K Price, et al.
American Journal of Clinical and Experimental Urology|June 3, 2021
Diversity on demand: multi-ancestry meta-analysis improves genetic risk prediction in prostate cancerAndres F Leon, Cindy H Chau, Douglas K Price, et al.
American Journal of Clinical and Experimental Urology|September 15, 2020
BETting on next-generation bromodomain inhibitorsMatthew K Collins, Cindy H Chau, Douglas K Price, et al.
Cancers|May 5, 2021
Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease ManagementDavid K Doan, Keith T Schmidt, Cindy H Chau, et al.
Pageof 8